Bioplex 2200 celiac iga

Serum IgA tissue anti-transglutaminase antibodies (tTG) (or IgG tTG in IgA-deficient patients) were analyzed using homologated commercial quantitative automated ELISAs while the patients were on a gluten-containing diet at the time of the diagnosis (during the 23 years considered for patient recruitment). Depending on the center, Elia Celikey IgA (Thermo Fisher, Phadia AB, Uppsala, Sweden), Aeskulisa tTg-A (Aesku Diagnostics, Wendelsheim, Germany), or Bioplex 2200 Celiac IgA (Bio-Rad, Hercules, CA, USA) were mainly used. Little change in sensitivity was expected. Serum anti-endomysium IgA antibodies (EmA) were tested by an IF assay at a dilution of 1:5 in commercial sections of primate distal esophagus as the antigen substrate (Immco Diagnostics, Buffalo, NY, USA) to confirm a positive result in all samples analyzed with the Aeskulisa tTG-A kit. In the remaining centers, EmA was tested in patients with either borderline anti-tTG or detectable anti-tTG titers that were below the cut-off suggested by the manufacturer to confirm positive celiac serology.

Serum IgA tTG (or IgG tTG in IgA deficient patients) was analysed using homologated commercial quantitative automated ELISAs while the patients were on a gluten-containing diet. Depending on the centre, EliA Celikey IgA (Thermo Fisher, Phadia AB, Uppsala, Sweden), Aeskulisa tTg-A (Aesku.Diagnostics, Wendelsheim, Germany) or Bioplex 2200 Celiac IgA (BioRad, Hercules, CA, USA) were used. Serum EmA was tested by an IF assay at dilution 1:5 in commercial sections of primate distal oesophagus as the antigen substrate (Immco Diagnostics, Buffalo, NY, USA) to confirm a positive result in all samples analysed with the Aeskulisa tTg-A kit. In the remaining centres, EmA was tested in patients with either borderline anti-tTG titres or detectable anti-tTG titres, but below the cut-off suggested by the manufacturer.